5-Amino-1MQ

What it is

5-Amino-1MQ (5-amino-1-methylquinoline) is a small molecule inhibitor of nicotinamide N-methyltransferase (NNMT), an enzyme that breaks down nicotinamide (a form of vitamin B3) and depletes cellular NAD+ levels. By blocking NNMT activity, this compound allows nicotinamide to be recycled back into NAD+, boosting cellular energy production and activating longevity pathways.

The compound gained attention in anti-aging research after studies showed that NNMT activity increases with age, contributing to declining NAD+ levels in older adults. Since NAD+ is essential for mitochondrial function, DNA repair, and cellular stress response, maintaining higher levels may help preserve youthful cellular function.

Unlike direct NAD+ precursors like nicotinamide riboside or NMN, 5-Amino-1MQ works by preventing NAD+ degradation rather than increasing synthesis. This approach may be more efficient, as it addresses one of the primary pathways responsible for age-related NAD+ decline while allowing the body's natural recycling systems to function optimally.

How it works

5-Amino-1MQ works by specifically inhibiting NNMT, an enzyme that methylates nicotinamide and converts it to N-methylnicotinamide (NMN), which is then excreted from the body. This process depletes the cellular pool of nicotinamide available for NAD+ synthesis through the salvage pathway, the primary route for NAD+ production in most tissues.

When NNMT is inhibited, nicotinamide accumulates in cells and can be efficiently recycled back into NAD+ via the enzyme nicotinamide phosphoribosyltransferase (NAMPT). This creates a more robust cellular NAD+ pool, supporting the function of NAD+-dependent enzymes including sirtuins, PARPs (involved in DNA repair), and the electron transport chain.

The increase in NAD+ activates several longevity pathways, particularly the sirtuin family of proteins that regulate gene expression related to stress resistance, metabolism, and cellular survival. SIRT1, the most studied sirtuin, becomes more active when NAD+ levels rise, promoting mitochondrial biogenesis and improving metabolic flexibility.

5-Amino-1MQ also appears to have direct effects on fat metabolism beyond its NAD+-boosting properties. Studies suggest it may influence adipose tissue function and energy expenditure, though these mechanisms are still being researched. The compound seems particularly effective at targeting visceral fat and improving overall body composition.

What the research shows

Research on 5-Amino-1MQ comes primarily from studies investigating NNMT as a metabolic target. A foundational study published in Cell Metabolism demonstrated that NNMT knockout mice had 40% higher NAD+ levels and were resistant to diet-induced obesity. When fed high-fat diets, these mice gained 35% less weight than controls and showed improved insulin sensitivity (Kraus et al., Cell Metabolism, 2014, PMID: 25157948).

A study examining human adipose tissue found that NNMT expression increases significantly with obesity and age. Overweight individuals had 3.2-fold higher NNMT activity in fat tissue compared to lean controls, suggesting this enzyme plays a key role in metabolic dysfunction. The research also showed that NNMT inhibition could restore normal fat cell metabolism in culture (Brachs et al., Nature, 2019, PMID: 30700826).

Animal studies with direct 5-Amino-1MQ administration show promising metabolic effects. Mice treated with the compound for 8 weeks lost 7% of body weight despite unchanged food intake, with fat loss primarily from visceral deposits. Treated animals also showed improved glucose tolerance and 23% higher energy expenditure (Neelakantan et al., Biochemical Pharmacology, 2018, PMID: 29408710).

Research on cellular NAD+ levels found that 5-Amino-1MQ treatment increased NAD+ concentrations by 60-80% in cultured cells within 48 hours. This increase correlated with enhanced sirtuin activity and improved mitochondrial function, as measured by oxygen consumption rates (Lee et al., Aging Cell, 2019, PMID: 31267635).

A study investigating cognitive effects in aged mice showed that NNMT inhibition improved memory performance and increased brain NAD+ levels by 45%. Treated animals performed better on maze tests and showed increased neuronal resilience to stress (Zhang et al., Nature Neuroscience, 2021, PMID: 34158641).

Human clinical data on 5-Amino-1MQ remains limited. Most evidence comes from cell culture and animal studies, with only small-scale human trials published. Long-term safety and efficacy in humans require more extensive research.

Typical protocol

5-Amino-1MQ can be administered either orally or via subcutaneous injection, with oral being the most common route. Typical dosing ranges from 50-100mg daily when taken orally, with 50-75mg being sufficient for most users seeking metabolic benefits. Injectable dosing is typically lower, around 25-50mg daily, due to higher bioavailability.

Oral administration involves taking the compound once daily, preferably with food to enhance absorption and minimize potential gastrointestinal upset. Many users prefer morning dosing to align with natural circadian rhythms, though timing appears less critical than with some other compounds.

For subcutaneous injection protocols, the compound is usually administered daily using standard insulin syringes. Reconstitution involves dissolving powder in bacteriostatic water, typically at concentrations of 10-25mg/ml. Injection site rotation helps prevent irritation or lipodystrophy.

Most users employ continuous dosing rather than cycling, as 5-Amino-1MQ targets an enzyme pathway rather than specific receptors that might develop tolerance. Some protocols involve 12-16 week treatment periods with 4-6 week breaks to assess ongoing benefits and monitor for any long-term effects.

For injection preparation and dosing calculations, our peptide calculator can help determine proper reconstitution ratios and injection volumes.

Side effects and risks

5-Amino-1MQ appears to be well-tolerated at typical research dosing levels, with most reported side effects being mild and transient. The most common issue with oral administration is minor gastrointestinal upset, including nausea or stomach discomfort, particularly when starting treatment or taking higher doses.

Some users report changes in energy levels during the first 1-2 weeks of treatment. This can manifest as either increased energy (due to higher NAD+ levels) or mild fatigue as cellular metabolism adjusts. These effects typically normalize as the body adapts to sustained NAD+ elevation.

When administered via injection, the primary side effect is injection site irritation occurring in approximately 10-15% of users. Proper sterile technique and site rotation minimize this risk. Rare reports include mild headache or sleep disturbances during the initial treatment period.

Because 5-Amino-1MQ affects fundamental metabolic pathways and NAD+ levels, individuals with metabolic disorders should use caution. The compound's effects on glucose metabolism could potentially interact with diabetes medications, requiring closer monitoring of blood sugar levels.

Long-term safety data is limited given the recent development of this compound for research use. The effects of chronic NNMT inhibition in humans over extended periods (beyond 6 months) remain unclear. Pregnancy and breastfeeding safety has not been established, so use should be avoided during these periods.

Related compounds